AstraZeneca Reaches Obesity Drug Deal; Imfinzi Combination Meets Main Goal In Liver Cancer Trial

(RTTNews) - AstraZeneca Plc. (AZN.L, AZN) and Eccogene have reached an exclusive license agreement for ECC5004, an investigational oral once-daily glucagon-like peptide 1 receptor agonist (GLP-1RA) for the treatment of obesity, type-2 diabetes and other cardiometabolic conditions https://www.nasdaq.com/articles/astrazeneca-reaches-obesity-drug-deal-imfinzi-combination-meets-main-goal-in-liver-cancer